

Enrolment Form



New Enrolment Prescription Renewal

Fax the completed form to 1.888.987.2201

Patient Information (patient to complete)

Mr Mrs Miss Ms

Last Name _____

Given Name _____

Date of Birth (dd/mm/yyyy) _____ / _____ / _____

Contact Information Please fill in all numbers Message ok? Best time to call

Home Phone (____) _____ - _____ _____

Work Phone (____) _____ - _____ _____

Cell Phone (____) _____ - _____ _____

Preferred Language: _____

City _____

Province _____ Postal Code _____

Optional Injection Training (physician to complete)

I would like an Enliven® nurse to train this patient on self-injection

Yes No

Location Patient's Home Office/Clinic

Address _____

Specific Requirements for Injection Training _____

Is the patient on beta-blockers*? Yes No

Please specify any allergies* _____

Other _____

* Information requirement for nursing service only.

A follow-up report on the injection training visit will be faxed to your office by Enliven, upon completion.

Consent

We respect your right to privacy. Adjuvant₂ (a division of World Travel Protection Canada Inc.) is the administrator of the Enliven Program ("Program"). The personal information you provide to Adjuvant₂, including your personal health information, such as name, contact information, and prescription information, will be used to provide you with the Program services, including reimbursement assistance, administering, training or assisting in therapy (e.g. self-injection training), and to allow Adjuvant₂ to conduct confidential surveys, from time to time, about the Program.

For these sole purposes, Adjuvant₂ may disclose your personal information on a confidential basis to: (i) Amgen Canada Inc. ("Amgen") and Pfizer Canada Inc. ("Pfizer"), the distributors of ENBREL (etanercept), to facilitate delivery of the Program services; and/or (ii) authorized agents and service providers. Please note that these service providers (e.g. information technology providers) and Amgen/Pfizer may store or process your data outside of Canada and may therefore be subject to additional local legislation. Other jurisdictions may have laws and regulations that require the disclosure of personal information to governmental authorities under different circumstances than would Canada. In addition, your personal information may be disclosed to Amgen/Pfizer or other third parties when permitted or required by applicable laws, court orders or government regulations (collectively, "Applicable Laws").

Adjuvant₂ and Amgen/Pfizer will retain your personal information only for the time required to fulfil the purposes for which it was collected and in order to comply with Applicable Laws. Adjuvant₂ and Amgen/Pfizer use industry standard safeguards to protect the security of the personal information that we collect. You may contact Adjuvant₂'s Privacy Officer at 1-877-936-2735 at any time to update or access your personal information, modify or withdraw your consent (in part or in full), express a privacy-related concern, or inquire about our privacy practices for the Program. Please note that if you modify or withdraw your consent, Adjuvant₂'s ability to deliver the Program services to you may be limited.

Physician Information

Physician Name _____

Site # (if applicable) _____

Phone Number _____

Fax Number _____

Prescription Information

ENBREL® Format

SureClick® Autoinjector Prefilled syringe

Lyophilized vial

Recommended dose of ENBREL

Dosing for plaque psoriasis

Starting

50 mg twice weekly (administered 3-4 days apart) x 3 months

Maintenance

50 mg once weekly

Other _____

Dosing for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

50 mg once weekly

Other _____

Dosing for juvenile idiopathic arthritis

0.8 mg/kg per week (up to 63 kg [138 lb]) to a maximum of 50 mg per week, or

50 mg once weekly

Other _____

STAMP

Other information/office stamp

Physician Signature _____

Date _____

CONSENT

By signing this form, I acknowledge that I have read and understand the above information and consent to the collection, use and disclosure of my personal information, including personal health information, by Adjuvant₂, Amgen/Pfizer and their authorized agents and service providers, as explained above. I further consent to being contacted from time to time by Adjuvant₂, Amgen/Pfizer or their authorized agents for the above-noted purposes.

Patient Signature _____ Date _____

Patient Name _____

This document may contain privileged and confidential information and is intended only for the person(s) named above. If you are not a named addressee, you should not disseminate, distribute or copy this document. If you have received this document by mistake, please notify the sender immediately and then destroy this document. We thank you for your cooperation and assistance. / Le présent document est destiné à la seule personne nommée ci-dessus et son contenu peut être privilégié et confidentiel. Si vous n'êtes pas le destinataire autorisé du document, il vous est interdit de l'utiliser, de le divulguer ou de le copier. Si vous avez reçu ce document par erreur, prière d'en aviser immédiatement l'expéditeur et d'en effacer toutes les copies. Nous vous remercions de votre coopération.

ENBREL® and Enliven® are registered trademarks of Immunex Corporation and SureClick® is a registered trademark of Amgen Inc., all used with permission.

© 2011 Pfizer Canada Inc. and Amgen Canada. All rights reserved.

To self-enrol in Enliven,
call 1.877.9ENBREL (1.877.936.2735)
or visit enbrel.ca

